ID   D458 Med
AC   CVCL_1161
SY   D-458 Med; D-458MED; D458MED; D458Med; Med 458; D-458; D458
DR   ArrayExpress; E-MTAB-783
DR   BioGRID_ORCS_Cell_line; 1664
DR   cancercelllines; CVCL_1161
DR   Cell_Model_Passport; SIDM01493
DR   Cosmic; 946381
DR   DepMap; ACH-001054
DR   GEO; GSM919360
DR   GEO; GSM1234976
DR   GEO; GSM1234977
DR   IARC_TP53; 27691
DR   Progenetix; CVCL_1161
DR   Wikidata; Q54817230
RX   PubMed=1822845;
RX   PubMed=1904513;
RX   PubMed=9283596;
RX   PubMed=20164919;
RX   PubMed=20847082;
RX   PubMed=22343310;
RX   PubMed=24297863;
RX   PubMed=27498314;
RX   PubMed=27812533;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 3.45 days (PubMed=1904513).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=22343310).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Cerebrospinal fluid; UBERON=UBERON_0001359.
DI   NCIt; C129445; Medulloblastoma, non-WNT/non-SHH, group 3
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1275 ! D425 Med
SX   Male
AG   6-7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 24
//
RX   PubMed=1822845;
RA   Wikstrand C.J., Friedman H.S., Bigner D.D.;
RT   "Medulloblastoma cell-substrate interaction in vitro.";
RL   Invasion Metastasis 11:310-324(1991).
//
RX   PubMed=1904513;
RA   He X.-M., Wikstrand C.J., Friedman H.S., Bigner S.H., Pleasure S.J.,
RA   Trojanowski J.Q., Bigner D.D.;
RT   "Differentiation characteristics of newly established medulloblastoma
RT   cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable
RT   xenografts.";
RL   Lab. Invest. 64:833-843(1991).
//
RX   PubMed=9283596; DOI=10.1016/S0165-4608(96)00404-9;
RA   Bigner S.H., McLendon R.E., Fuchs H.E., McKeever P.E., Friedman H.S.;
RT   "Chromosomal characteristics of childhood brain tumors.";
RL   Cancer Genet. Cytogenet. 97:125-134(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20847082; DOI=10.1093/neuonc/noq091;
RA   Teider N., Scott D.K., Neiss A., Weeraratne S.D., Amani V.M., Wang Y.-F.,
RA   Marquez V.E., Cho Y.-J., Pomeroy S.L.;
RT   "Neuralized1 causes apoptosis and downregulates Notch target genes in
RT   medulloblastoma.";
RL   Neuro-oncol. 12:1244-1256(2010).
//
RX   PubMed=22343310; DOI=10.1016/j.neulet.2012.02.022;
RA   Ghassemifar S., Mendrysa S.M.;
RT   "MDM2 antagonism by nutlin-3 induces death in human medulloblastoma
RT   cells.";
RL   Neurosci. Lett. 513:106-110(2012).
//
RX   PubMed=24297863; DOI=10.1158/1078-0432.CCR-13-2281;
RA   Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S.,
RA   Tang Y.-J., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F.-R.,
RA   Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J.,
RA   Liu K.-W., Wechsler-Reya R.J., Weiss W.A., Swartling F.J., Kieran M.W.,
RA   Bradner J.E., Beroukhim R., Cho Y.-J.;
RT   "BET bromodomain inhibition of MYC-amplified medulloblastoma.";
RL   Clin. Cancer Res. 20:912-925(2014).
//
RX   PubMed=27498314; DOI=10.1016/j.jbiotec.2016.07.028;
RA   Ivanov D.P., Coyle B., Walker D.A., Grabowska A.M.;
RT   "In vitro models of medulloblastoma: choosing the right tool for the
RT   job.";
RL   J. Biotechnol. 236:10-25(2016).
//
RX   PubMed=27812533; DOI=10.1016/j.dib.2016.10.004;
RA   Ivanov D.P., Walker D.A., Coyle B., Grabowska A.M.;
RT   "Data on the number and frequency of scientific literature citations
RT   for established medulloblastoma cell lines.";
RL   Data Brief 9:696-698(2016).
//